The ISCTM (International Society for CNS Clinical Trials and Methodology) conference in Washington, DC is one of the most significant gatherings in the CNS clinical trials field, hosting hundreds of experts from academia, industry, and regulatory agencies to tackle pressing challenges in clinical trial methodology.
As long-time members and advocates for ISCTM, as well as global leaders in CNS trial optimization, Signant Health is looking forward to exchanging ideas and sharing success stories with the CNS research community.
Get a look at our latest CNS research during our poster sessions:
Martina Micaletto, Program Manager Clinical Science
Examining patterns of commonly observed quality issues across global schizophrenia clinical trial research sites.
Alan Kott, Practice Leader Data Analytics
The impact of PANSS change in screening on week 1 PANSS change in acute schizophrenia clinical trials.
David Daniel, Head of CNS Medicine
Comparison of the ten-item pediatric Positive and Negative Syndrome Scale (PANSS-10) to the PANSS-6 in an adult, acutely exacerbated clinical trial population with schizophrenia.
Receive our poster presentations when available:
Our clinical & science experts at ISCTM
DAVID DANIEL, MD
EXECUTIVE ADVISOR, SCHIZOPHRENIA
Dr. Daniel has over 25 years of experience overseeing rater training and data quality management programs in various settings. He has supervised countless clinical trials for schizophrenia and bipolar disorder. In addition to his work with Signant, David serves as Clinical Professor of Psychiatry at George Washington University.
Roger Smith
Chief Executive Officer
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Dr. Busner has over 35 years of experience as an academic psychiatric researcher and psychopharmacology principal investigator, and founded and directed two university psychiatric clinical trials units. Dr. Busner served continuously on University Institutional Review Boards for 20 years. At Signant she has scientific and clinical responsibility for studies in mood, anxiety, pediatrics, and rare/orphan diseases. She has overseen hundreds of trials and trained thousands of raters. Dr. Busner is currently Affiliate Associate Professor of Psychiatry at Virginia Commonwealth University.
Dr. Miller is a geriatric psychiatrist by training. He has over 25 years of experience in patient care, clinical research, teaching, and even served as a principal investigator for dementia studies. David currently serves as the Chair of the Alzheimer’s Association Research Roundtable.
Dr. Kott is based in Signant’s Prague office and until recently was Senior Clinical Manager for Europe. Having led the development of the Data Analytics Program for Bracket, he has overseen the design and reporting of data analytics in multiple large schizophrenia studies. For the past seven years, he has also provided training to investigators as an Expert Trainer.
Dr. Elias Ketiar serves as the Clinical Vice President, Science & Medicine, at Signant Health. Dr. Ketiar draws on his wealth of more than 20 years of academic and clinical experience to advise on clinical trial design, execution, and governance.
He has extensive experience in General Internal Medicine and Cardiology and is a Member of Royal College of Physicians (London), UK. Dr Ketiar has been engaged in academic research and was involved in a pioneering project investigating genetic causes of congenital heart disease, which culminated in a Medical Doctorate with St George’s University of London, UK.
He also has peer reviewed papers published. He has always been involved in all phases of clinical development and interested in global clinical trial solutions.
Greta is a Senior Clinical Scientist at Signant Health, providing scientific expertise and guidance relating to the implementation of electronic clinical outcome assessments (eCOAs), with a special focus on eDiary design and accessibility of eCOA best practices. She completed her PhD in Physiological Sciences at Stellenbosch University, which focused on the bacterial and inflammatory involvement in colorectal carcinogenesis, and has 3+ years’ experience in the clinical research industry. She has given scientific consultation for projects across a wide range of therapeutic areas, including oncology, infectious disease, dermatology, and gastroenterology.
Dr. Kusanto studied bioengineering at Oregon State University before completing his PhD in platelet biology at Hull York Medical School. At Signant, he specializes in eCOA, eConsent, and multiple therapeutic areas like, dermatology, gastroenterology, pediatrics, and rare diseases.
Antonina is a Clinical Scientist at Signant Health, where she leverages her extensive experience as a pharmacist, biomedical scientist, and clinical researcher to advance the field of clinical trials. Her career is marked by a dedicated focus on the safety of trial participants, ensuring that rigorous standards are met across all studies. Antonina thrives in cross-disciplinary environments that blend scientific expertise with innovative problem-solving, constantly seeking to learn new skills and adopt fresh approaches. Her passion for the clinical trials sector is evident in her commitment to enhancing the safety and efficacy of research, making her a pivotal figure in the ongoing quest for medical advancements.